ODS vs Tablets: Disintegration Time Compared

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

A compressed tablet must disintegrate before any of its dose can absorb, and immediate-release tablets are allowed up to 30 minutes for that step under USP General Chapter <701> (USP, 2019). In-vivo imaging shows real tablet disintegration averaging 10 to 26 minutes (Fredholt et al., 2022). An oral dissolving strip (ODS) hydrates and disintegrates in saliva within 30 to 60 seconds, requires no water, and bypasses gastric emptying entirely (Hoffmann et al., 2011). Up to 40 percent of adults report difficulty swallowing solid pills (Schiele et al., 2013). MIHIYO Labs uses the ODS format where speed, water-free dosing, and predictable mucosal contact matter.

How long does a tablet take to disintegrate vs a strip?

The direct answer: a standard immediate-release compressed tablet is permitted up to 30 minutes to disintegrate under United States Pharmacopeia General Chapter <701>, and in-vivo human imaging studies put the real disintegration window at roughly 10 to 26 minutes depending on formulation (Fredholt et al., Int J Pharm, 2022). An oral dissolving strip (ODS) — a thin polymer film loaded with active ingredient — hydrates on contact with saliva and disintegrates within approximately 30 to 60 seconds, with no water required (Hoffmann et al., Expert Opin Drug Deliv, 2011; Bala et al., Int J PharmTech Res, 2013).

That is a one-to-two-order-of-magnitude difference in the time before any of the dose is available for absorption. The reason for the gap is not chemistry — it is physics. A tablet is a dense, compressed solid that must first break apart in fluid; a strip is a thin polymer matrix that hydrates almost on contact.

Why a compressed tablet takes minutes to break apart

A compressed tablet is manufactured by applying high mechanical pressure to a powder blend in a steel die. The resulting solid is dense, low in porosity, and held together by binders — pharmaceutical excipients like povidone, microcrystalline cellulose, or hydroxypropylmethylcellulose that create cohesive bonds between particles during compression. The same binders that make a tablet survive shipping and bottle handling are also what slow down its disintegration once swallowed.

To compensate, formulators add disintegrants — excipients like crospovidone, croscarmellose sodium, or sodium starch glycolate that swell or wick water when the tablet enters fluid. Disintegrants and binders have opposing roles in the same dosage form: binders hold the tablet together; disintegrants force it apart once it reaches the gut. The final disintegration time is the net of those two competing forces, plus the volume and pH of the fluid the tablet lands in.

For an immediate-release tablet, the USP test protocol (USP <701>) places one unit into each of six glass tubes in a basket-rack assembly, immerses the assembly in water or simulated gastric fluid at 37°C, and raises and lowers the basket at a fixed rate. All six tablets must fully disintegrate within the time limit — 30 minutes for uncoated immediate-release tablets, with shorter limits for orally disintegrating tablets and longer limits for sustained-release forms (USP, General Chapter <701>, 2019). The British Pharmacopoeia uses a 15-minute limit for uncoated tablets; the same harmonized assembly is used.

In-vivo data from human volunteers confirms the test reflects real biology. A 2022 endoscopic study by Fredholt et al. (Int J Pharm) attached miniaturized cameras to immediate-release paracetamol tablets and recorded disintegration directly inside the stomach: a standard conventional tablet (Panodil®) took 26 ± 13 minutes; a rapid-release formulation (Panodil® Zapp) took 10 ± 7 minutes. A separate scintigraphy study of hard gelatin capsules — for context — reported 7 ± 5 minutes in fasted volunteers and 11 ± 7 minutes after a meal (Cole et al., J Clin Pharm Ther, 2004). The tablet is the slowest of the common immediate-release forms because of compression density.

Why a strip disintegrates in seconds

An oral dissolving strip is a thin film, typically 50 to 200 micrometers thick, composed of a film-forming hydrophilic polymer (commonly hydroxypropylmethylcellulose, pullulan, or sodium alginate), a plasticizer, the active ingredient, and small amounts of sweeteners or flavors. The polymer is selected for one property above all: rapid hydration. When the strip contacts the moist oral mucosa, the polymer chains hydrate, swell, and disengage — the film dissolves rather than fracturing (Hoffmann et al., Expert Opin Drug Deliv, 2011; Karki et al., Asian J Pharm Sci, 2016).

The geometry helps. A film has a surface-area-to-volume ratio orders of magnitude higher than a compressed tablet of equivalent dose. Saliva penetrates the matrix from both faces almost immediately, and the entire film disintegrates from the surface inward in tens of seconds. Reported in-vitro disintegration times for well-formulated ODFs cluster between 5 and 60 seconds, with most commercial and research films falling under 30 to 120 seconds depending on polymer choice and thickness (Pawar et al., Pharmazie, 2019; Bala et al., 2013). Strips do not require gastric emptying, do not require water, and do not require the swallow reflex to occur before dose release begins.

What the data actually shows: the spine comparison

Below is the comparison spine. Every row carries a sourced number and is explained immediately after the table.

Disintegration time — regulatory and measured. The 30-minute limit in USP <701> is a ceiling, not a typical value. Most modern immediate-release tablets disintegrate well inside that window, but the ceiling exists because density, binder choice, and storage conditions can push a real tablet to the edge of the specification. The 2022 endoscopic study by Fredholt et al. is the cleanest direct measurement available: conventional paracetamol tablets averaged 26 minutes; even the rapid-release variant averaged 10 minutes. An ODS, by contrast, is engineered for sub-minute disintegration; published research films report mean disintegration times in the 30 to 60 second range, with some specific formulations measured at 44 seconds (Bala et al., 2013).

Water requirement. The recommended minimum volume of water for safely swallowing a tablet or capsule is 50 to 60 mL, because volumes below ~30 mL can allow a dosage form to adhere to the esophageal wall (Schiele et al., 2013, Pharm World Sci). The same authors found in a cross-sectional study that 15.4% of participants used 60 mL or less to take their oral solids — already at or below the safe minimum. An ODS removes the variable entirely: no water is required, because the polymer matrix dissolves directly in saliva.

Onset of dose availability. Compressed tablets must clear three serial steps before any drug can absorb: gastric emptying (highly variable, from under 10 minutes fasted to over 90 minutes after food), tablet disintegration (the 10 to 26 minutes above), and dissolution of the released particles into gastric or intestinal fluid. An ODS skips gastric emptying entirely and begins releasing API on first contact with oral mucosa — a vascularized, non-keratinized epithelium that is among the most permeable mucosal surfaces in the body (Hearnden et al., Adv Drug Deliv Rev, 2012; Patel et al., Int J Pharm Investig, 2011). For compounds that absorb across the mucosa, this means dose availability starts in seconds rather than tens of minutes.

Patient swallowing burden. A systematic review by Marquis et al. (Pharmaceutics, 2023) and the cross-sectional Schiele et al. study together place the prevalence of pill-swallowing difficulty in adults at up to 40 percent of the general population, with substantially higher rates in older adults and aged-care residents. Pill dysphagia leads to skipped doses in 23 to 69 percent of affected individuals. A film that dissolves in the mouth without a swallow reflex sidesteps that compliance problem entirely.

Dose-form stability. This row goes to the tablet. A compressed tablet, properly packaged, is typically stable at room temperature for two to three years; this is one reason tablets remain the dominant pharmaceutical dosage form globally. ODFs are more moisture-sensitive — the same hydrophilic polymers that make them dissolve in saliva also make them absorb humidity from the air. Foil unit-dose packaging is the standard solution and works well, but the format has a real limitation here (Hoffmann et al., 2011).

What this means for the MIHIYO Energy-Focus strip

The MIHIYO Labs Energy-Focus ODS is designed to dissolve against the inner cheek or under the tongue over approximately 60 to 90 seconds. The polymer matrix is selected for rapid hydration; the active is held in close contact with the mucosa for the entire dissolution window rather than being released into a fluid bolus to be swallowed.

The pharmacological case for this format, for caffeine specifically, was covered in a prior article on caffeine strip onset: the buccal contact time advantage is about when the dose becomes available, not how much. The same logic applies in this article — the tablet route delays availability by 10 to 30 minutes; the strip route shortens that to under a minute and removes the gastric-emptying variable.

I want to be direct about the evidence base. The pharmacopeia disintegration data, the endoscopic tablet study, and the ODF disintegration ranges cited here come from research on independent dosage forms — not on MIHIYO products. There is no published human pharmacokinetic study on the MIHIYO Energy-Focus strip. What is generalizable is the physics of the dosage form itself: a thin hydrophilic film dissolves in seconds; a compressed tablet does not.

For broader context on why dosage form matters across the supplement category, see the foundational article on sublingual vs oral absorption, and on dose precision specifically, the melatonin strip dosage article.

Where compressed tablets win — and they often do

This article would be dishonest if it ended at "strips are faster, choose strips." Tablets remain the dominant pharmaceutical dosage form because they win on several real dimensions, and acting like they don't would be wrong.

Tablets win on dose ceiling. A compressed tablet can carry hundreds of milligrams — or grams — of active ingredient in a single unit. A 500 mg paracetamol tablet, a 1,000 mg metformin tablet, a 1,500 mg calcium carbonate tablet — these doses do not fit in a film. ODF active loading is typically capped at the low tens of milligrams per strip; high-dose actives are mechanically incompatible with the format.

Tablets win on sustained and modified release. A controlled-release matrix tablet, an enteric-coated tablet that bypasses the stomach to release in the intestine, a multi-layer tablet with sequential active release — these are mature, well-understood technologies built on the tablet form factor. The strip dissolves too fast to host most of these release profiles.

Tablets win on cost and scale. Tablet presses produce tens of thousands of units per hour at extremely low marginal cost. ODF manufacturing (solvent casting, hot-melt extrusion) is more specialized and has lower throughput per dollar of capital equipment. For a low-cost commodity active where speed of onset is not the dominant variable, the tablet is the right answer.

Tablets win on long-term stability. As noted above, properly packaged tablets are stable for years; ODFs are humidity-sensitive and require protective packaging. For a global supply chain into hot, humid markets, this is a real consideration.

The right framing is not "strips are better than tablets." It is "strips are better than tablets when the variables that matter are speed of disintegration, no water required, low to moderate dose, and predictable mucosal contact." For high-dose, modified-release, or pure-cost-driven products, the tablet wins. Both formats are tools.

The bottom line on oral dissolving strip vs tablet

A compressed tablet is permitted up to 30 minutes to disintegrate under USP standards and typically takes 10 to 26 minutes inside the stomach. An oral dissolving strip dissolves in 30 to 60 seconds in saliva, with no water and no swallow reflex required. The two formats are not interchangeable: tablets remain the right choice for high-dose, modified-release, and pure-cost applications, while strips are the right choice when speed, water-free dosing, and predictable mucosal contact are the variables that matter. The honest framing is not strip versus tablet — it is matching dosage form to the actual pharmacological and practical requirement.

References

1. United States Pharmacopeia. General Chapter <701> Disintegration. USP Pharmacopeial Forum, harmonized text (April 2019). <https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/april-2019-m99460.pdf>

1. Fredholt F, Di Meo C, Sloth S, Müllertz A, Berthelsen R. Direct visualizing of paracetamol immediate release tablet disintegration in vivo and in vitro. Int J Pharm. 2022;625:122068. PMID: 36122785. <https://pubmed.ncbi.nlm.nih.gov/36122785/>

1. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. PMID: 21284577. <https://pubmed.ncbi.nlm.nih.gov/21284577/>

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67-76. PMID: 24015378. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3757902/>

1. Schiele JT, Quinzler R, Klimm H-D, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69(4):937-948. PMID: 23052416. <https://pubmed.ncbi.nlm.nih.gov/23052416/>

1. Marquis J, Schneider M-P, Payot V, et al. Adult Patients with Difficulty Swallowing Oral Dosage Forms: A Systematic Review of the Quantitative Literature. Pharmaceutics. 2023;15(5):1457. PMID: 37888511. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10609855/>

1. Hearnden V, Sankar V, Hull K, et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev. 2012;64(1):16-28. PMID: 21371513. <https://pubmed.ncbi.nlm.nih.gov/21371513/>

1. Pawar HA, Kamat SR, Choudhary PD. Disintegration time of orally dissolving films: various methodologies and in-vitro/in-vivo correlation. Pharmazie. 2019;74(4):207-212. PMID: 30940306. <https://pubmed.ncbi.nlm.nih.gov/30940306/>

1. Karki S, Kim H, Na S-J, Shin D, Jo K, Lee J. Thin films as an emerging platform for drug delivery. Asian J Pharm Sci. 2016;11(5):559-574. <https://www.sciencedirect.com/science/article/pii/S1818087616300447>

1. Almukainzi M, Salehi M, Bou-Chacra NA, Löbenberg R. Investigation of the performance of the disintegration test for dietary supplements. AAPS J. 2010;12(4):602-607. PMID: 20652779. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2977009/>